Morgan Stanley raised shares to overweight rating for a potential joint venture involving TSMC and Odysight.ai, while Benchmark reaffirmed a buy rating.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley raised shares to overweight rating for a potential joint venture involving TSMC and Odysight.ai, while Benchmark reaffirmed a buy rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- TSMC formed a joint venture valued at $4.7 Billion in Buy.Sub-event
Morgan Stanley and Benchmark issue ratings regarding joint venture potential between TSMC and Odysight.ai.1 source
Keep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
TSMC
semiconductor foundry company headquartered in Taiwan
-
Benchmark
venture capital firm
- The Bank of England, FED, and market experts are discussing how the ongoing Iran conflict and geopolitical tensions are driving up energy costs and influencing global financial rates.
- MarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.
Related events
- Morgan Stanley assumed coverage and upgraded shares to a strong-buy rating for Onto Innovation.
- Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.
- Morgan Stanley raised its price target and maintained an overweight rating for Wingstop.
- Morgan Stanley issued an underweight rating on Hess Midstream Partners LP.
- Morgan Stanley and Manufacturers Life Insurance Company purchased a new position and reiterated an overweight rating for Monopar Therapeutics.